Ignite Creation Date:
2024-05-06 @ 7:10 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02487316
Status:
WITHDRAWN
Last Update Posted:
2016-12-30
First Post:
2015-06-30
Brief Title:
A Study of Treatment ALK Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Sponsor:
Jun Zhu
Organization:
Peking University
Study Overview
Official Title:
A Multicenter Prospective Study of Treatment ALK Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Status:
WITHDRAWN
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK Systemic Anaplastic Large Cell Lymphoma
Detailed Description:
ALK Systemic Anaplastic Large Cell Lymphoma patients are treated with crizotinib when they receive CHOP chemotherapy crizotinib 250mg twice a day is administrated from day 1 of chemotherapy to 18 weeks standard CHOP chemotherapy cyclophosphamide 750mg per square meter of body-surface aread1 vincristine 14mg per square meter of body-surface area maximal dose is 2mg d1 doxorubicin 50mg per square meter of body-surface area d1 plus prednison 100 mg d1-5 every 3 weeks for up to six cycles
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None